KemPharm (KMPH) Posts Earnings Results, Misses Expectations By $0.17 EPS

Share on StockTwits

KemPharm (NASDAQ:KMPH) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.17), Morningstar.com reports.

KemPharm stock traded down $0.06 during mid-day trading on Friday, reaching $2.56. The company’s stock had a trading volume of 190,097 shares, compared to its average volume of 398,779. The company has a market cap of $41.87 million, a PE ratio of -0.86 and a beta of 0.86. KemPharm has a twelve month low of $2.00 and a twelve month high of $8.40.

A number of brokerages recently issued reports on KMPH. Oppenheimer set a $13.00 price target on shares of KemPharm and gave the stock a “buy” rating in a research note on Thursday, August 9th. Zacks Investment Research downgraded shares of KemPharm from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 price objective on shares of KemPharm in a report on Tuesday, August 14th. CIBC reaffirmed an “outperform” rating on shares of KemPharm in a report on Friday, September 21st. Finally, ValuEngine raised shares of KemPharm from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. KemPharm presently has an average rating of “Buy” and an average target price of $10.50.

In other KemPharm news, major shareholder Delaware Street Capital Master acquired 2,000,000 shares of the firm’s stock in a transaction on Friday, October 5th. The stock was purchased at an average price of $3.00 per share, with a total value of $6,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders acquired 2,012,650 shares of company stock valued at $6,032,461. 25.90% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in KemPharm in the first quarter worth $122,000. Spark Investment Management LLC acquired a new position in shares of KemPharm during the second quarter valued at $176,000. Royal Bank of Canada boosted its holdings in shares of KemPharm by 1,847.1% during the first quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock valued at $191,000 after acquiring an additional 22,886 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of KemPharm by 15,976.2% during the first quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock valued at $795,000 after acquiring an additional 100,011 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of KemPharm by 101.1% during the second quarter. Renaissance Technologies LLC now owns 181,800 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after acquiring an additional 91,400 shares during the period. 39.28% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Equities Focus and is the sole property of of Equities Focus. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.equitiesfocus.com/2018/11/10/kempharm-kmph-posts-earnings-results-misses-expectations-by-0-17-eps.html.

KemPharm Company Profile

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.

Further Reading: What does relative strength index mean?

Earnings History for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply